T cell experts at Kiadis bag CytoSen's NK cell tech, plotting a dual cancer killing approach with tips from Carl June
In an effort to marry T cell and natural killer cell technologies for the treatment of blood cancer, Dutch biotech Kiadis has inked an all-stock deal to acquire US-based CytoSen Therapeutics.
Both companies have had the same goal: to boost the chances of cancer patients undergoing hematopoietic stem cell transplants by supercharging their immune system while their bone marrow recovers from the procedure. Kiadis does this with engineered T cells; CytoSen chose NK cells, designed to attack any remaining malignant cells that could lead to a relapse. Both technologies take cells from a family member of the patient so that the immune cells would be partially matched.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.